Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors.
Martínez-González S, Alvarez RM, Martín JI, García AB, Riesco-Fagundo C, Varela C, Rodríguez Hergueta A, González Cantalapiedra E, Albarrán MI, Gómez-Casero E, Cebriá A, Aguirre E, Ajenjo N, Cebrián D, Di Geronimo B, Cunningham D, O'Neill M, Dave HPG, Blanco-Aparicio C, Pastor J. Martínez-González S, et al. Among authors: cunningham d. ACS Med Chem Lett. 2021 Nov 2;12(11):1794-1801. doi: 10.1021/acsmedchemlett.1c00412. eCollection 2021 Nov 11. ACS Med Chem Lett. 2021. PMID: 34795869 Free PMC article.
Proline specific peptidases.
Cunningham DF, O'Connor B. Cunningham DF, et al. Biochim Biophys Acta. 1997 Dec 5;1343(2):160-86. doi: 10.1016/s0167-4838(97)00134-9. Biochim Biophys Acta. 1997. PMID: 9434107 Review.
Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials.
Raimondi A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, Randon G, Kook MC, An JY, Grabsch HI, Prisciandaro M, Nichetti F, Noh SH, Sohn TS, Kim S, Wotherspoon A, Morano F, Cunningham D, Lee J, Cheong JH, Smyth EC, Pietrantonio F. Raimondi A, et al. Among authors: cunningham d. Eur J Cancer. 2024 May;203:114043. doi: 10.1016/j.ejca.2024.114043. Epub 2024 Apr 4. Eur J Cancer. 2024. PMID: 38598921
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Zinzani PL, Salles GA, Moskowitz AJ, Santoro A, Mehta A, Barr PM, Mehta-Shah N, Collins GP, Ansell SM, Brody JD, Domingo-Domenech E, Johnson NA, Cunningham D, Ferrari S, Lisano JM, Krajewski J, Wen R, Akyol A, Crowe R, Savage KJ. Zinzani PL, et al. Among authors: cunningham d. Blood Adv. 2024 Mar 26:bloodadvances.2023011030. doi: 10.1182/bloodadvances.2023011030. Online ahead of print. Blood Adv. 2024. PMID: 38531062 No abstract available.
Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE.
Cartwright E, Slater S, Saffery C, Tran A, Turkes F, Smith G, Aresu M, Kohoutova D, Terlizzo M, Zhitkov O, Rana I, Johnston EW, Sanna I, Smyth E, Mansoor W, Fribbens C, Rao S, Chau I, Starling N, Cunningham D. Cartwright E, et al. Among authors: cunningham d. ESMO Open. 2024 Apr;9(4):102971. doi: 10.1016/j.esmoop.2024.102971. Epub 2024 Mar 21. ESMO Open. 2024. PMID: 38518549 Free PMC article. Clinical Trial.
2,205 results